New combo therapy shows promise for tough rectal cancers
NCT ID NCT06770270
First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 33 times
Summary
This study tests whether adding an immunotherapy drug (pucotenlimab) to standard chemoradiation can help shrink advanced rectal cancers before surgery. About 68 adults with locally advanced rectal cancer will receive the combination treatment. The goal is to see if more patients achieve a complete response, meaning no cancer remains detectable after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital Of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.